Bio-Rad Laboratories (BIO) Reaches New 52-Week High and Low at $297.59

Bio-Rad Laboratories (NYSE:BIO) shares reached a new 52-week high and low on Monday . The stock traded as low as $297.59 and last traded at $294.60, with a volume of 853 shares. The stock had previously closed at $297.45.

BIO has been the subject of several research reports. Wells Fargo & Co increased their price target on Bio-Rad Laboratories from $280.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 20th. Citigroup increased their price target on Bio-Rad Laboratories to $325.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. CL King downgraded Bio-Rad Laboratories from a “buy” rating to a “neutral” rating in a research note on Friday, February 16th. ValuEngine upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Finally, Jefferies Group increased their price target on Bio-Rad Laboratories to $325.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $297.20.

The company has a debt-to-equity ratio of 0.10, a current ratio of 4.33 and a quick ratio of 2.99. The company has a market capitalization of $8.71 billion, a P/E ratio of 70.58, a PEG ratio of 3.18 and a beta of 0.95.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Tuesday, February 27th. The medical research company reported $1.50 EPS for the quarter, topping the consensus estimate of $1.28 by $0.22. Bio-Rad Laboratories had a return on equity of 3.84% and a net margin of 34.32%. The business had revenue of $620.43 million during the quarter, compared to the consensus estimate of $618.89 million. equities analysts forecast that Bio-Rad Laboratories will post 6.13 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Principal Financial Group Inc. boosted its stake in Bio-Rad Laboratories by 2.5% in the 1st quarter. Principal Financial Group Inc. now owns 88,336 shares of the medical research company’s stock worth $22,091,000 after purchasing an additional 2,127 shares during the period. Levin Capital Strategies L.P. bought a new position in Bio-Rad Laboratories in the 1st quarter worth about $3,412,000. Xact Kapitalforvaltning AB boosted its stake in Bio-Rad Laboratories by 45.1% in the 1st quarter. Xact Kapitalforvaltning AB now owns 2,572 shares of the medical research company’s stock worth $643,000 after purchasing an additional 800 shares during the period. Legal & General Group Plc boosted its stake in Bio-Rad Laboratories by 5.5% in the 1st quarter. Legal & General Group Plc now owns 28,325 shares of the medical research company’s stock worth $7,084,000 after purchasing an additional 1,476 shares during the period. Finally, Millennium Management LLC boosted its stake in Bio-Rad Laboratories by 52.9% in the 1st quarter. Millennium Management LLC now owns 275,220 shares of the medical research company’s stock worth $68,827,000 after purchasing an additional 95,218 shares during the period. Institutional investors and hedge funds own 65.27% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply